Eight Months And Counting: Santen Still Waiting For Final Marketing Decision On Drug Fast-Tracked By EMA

It has been eight months since the European Medicines Agency recommended market approval for a drug that was reviewed under its fast-track mechanism, but the sponsor has yet to receive a final decision from the European Commission. The company ran into problems when seeking to renew the drug's orphan status before approval.